A novel highly selective allosteric inhibitor of tyrosine kinase 2 (TYK2) can block inflammation- and autoimmune-related pathways

被引：0
|
作者：
Celia X.-J. Chen
Wei Zhang
Shulan Qu
Fucan Xia
Yidong Zhu
Bo Chen
机构：
[1] Shanghai Qilu Pharmaceutical R&D Center Limited,Department of Immunology and Inflammation
[2] Present address: China Resources Pharmaceutical Group Limited,undefined
来源：
Cell Communication and Signaling | / 21卷
关键词：
TYK2; JAK; Cytokine pathway; Pseudokinase regulatory domain; Allosteric inhibitor; Psoriasis; Autoimmune diseases;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 7 条
  • [1] A novel highly selective allosteric inhibitor of tyrosine kinase 2 (TYK2) can block inflammation- and autoimmune-related pathways
    Chen, Celia X. -J.
    Zhang, Wei
    Qu, Shulan
    Xia, Fucan
    Zhu, Yidong
    Chen, Bo
    CELL COMMUNICATION AND SIGNALING, 2023, 21 (01)
  • [2] Discovery of WD-890: A novel allosteric TYK2 inhibitor for the treatment of multiple autoimmune diseases
    Fang, Zhiqin
    Sun, Hongyin
    Wang, Yutong
    Sun, Zhenliang
    Yin, Mingzhu
    BIOMEDICINE & PHARMACOTHERAPY, 2023, 167
  • [3] Novel Small Molecule Tyrosine Kinase 2 Pseudokinase Ligands Block Cytokine-Induced TYK2-Mediated Signaling Pathways
    Zhou, Yu
    Li, Xin
    Shen, Ru
    Wang, Xiangzhu
    Zhang, Fan
    Liu, Suxing
    Li, Di
    Liu, Jian
    Li, Puhui
    Yan, Yinfa
    Dong, Ping
    Zhang, Zhigao
    Wu, Heping
    Zhuang, Linghang
    Chowdhury, Rasheduzzaman
    Miller, Matthew
    Issa, Mena
    Mao, Yuchang
    Chen, Hongli
    Feng, Jun
    Li, Jing
    Bai, Chang
    He, Feng
    Tao, Weikang
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [4] Pharmacodynamic Response to Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in a Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled Psoriasis Trial
    Catlett, Ian M.
    Gao, Lu
    Hu, Yanhua
    Banerjee, Subhashis
    Krueger, James G.
    DERMATOLOGY AND THERAPY, 2024, 14 (10) : 2827 - 2839
  • [5] Selective oral tyrosine kinase 2 (TYK2) inhibitor (BMS-986165) impact on quality of life (QOL) in patients with moderate to severe plaque psoriasis (PSO) in a phase 2 trial as assessed by the dermatology life quality index (DLQI)
    Thaci, D.
    Papp, K.
    Gordon, K.
    Morita, A.
    Gooderham, M.
    Foley, P.
    Kisa, R.
    Napoli, A.
    Kundu, S.
    Banerjee, S.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 : 71 - 72
  • [6] Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: A subset analysis of two phase 3 randomized trials in plaque psoriasis
    Blauvelt, Andrew
    Rich, Phoebe
    Sofen, Howard
    Strober, Bruce
    Merola, Joseph F.
    Lebwohl, Mark
    Morita, Akimichi
    Szepietowski, Jacek C.
    Lambert, Jo
    Hippeli, Lauren
    Colston, Elizabeth
    Balagula, Eugene
    Banerjee, Subhashis
    Thaci, Diamant
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2024, 90 (04) : 775 - 782
  • [7] Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Japanese patients with moderate to severe plaque, erythrodermic, or generalized pustular psoriasis: Efficacy and safety results from an open-label, phase 3 trial
    Imafuku, Shinichi
    Okubo, Yukari
    Tada, Yayoi
    Ohtsuki, Mamitaro
    Colston, Elizabeth
    Napoli, Andrew
    Shao, Yanqiu
    Banerjee, Subhashis
    Morita, Akimichi
    JOURNAL OF DERMATOLOGY, 2024, 51 (03) : 365 - 379
1